OBJECTIVE: To establish the prevalence of chronotropic incompetence in a cohort of patients with chronic heart failure (CHF) taking modern medications for heart failure, and whether this affected exercise capacity and predicted prognosis. METHODS: Heart rate response to exercise was examined in 237 patients with CHF in sinus rhythm, who were compared with 118 control volunteers. The percentage of maximum age predicted peak heart rate (%Max-PPHR) and percentage heart rate reserve (%HRR) were calculated, with a cut off of < 80% as the definition of chronotropic incompetence for both. Patients were followed up for an average (SD) of 2.8 (9) years. Mortality was related to peak oxygen consumption (pVo2), and the presence or absence of chronotropic incompetence. RESULTS: %Max-PPHR < 80% identified 103 (43%) and %HRR < 80% identified 170 patients (72%) as having chronotropic incompetence. Chronotropic incompetence was more common in patients taking beta blockers than in those not taking beta blockers as assessed by both methods (80 (49%) v 23 (32%) by %Max-PPHR and 123 (75%) v 47 (64%) by %HRR, respectively). Patients with chronotropic incompetence by either method had a lower pVo2 than those without. These differences remained significant for both patients taking and not taking a beta blocker. %HRR, Max-PPHR%, and HRR were related to New York Heart Association class and correlated with pVo2. There was no difference in the slopes relating heart rate to pVo2 between patients with and those without chronotropic incompetence (6.1 (1.7) v 5.1 (1.8), p = 0.34). During an average 2.8 year follow up 40 patients (17%) died. In Cox proportional hazard models, pVo2 was the most powerful predictor of survival and neither measure of chronotropic incompetence independently predicted outcome. CONCLUSIONS: pVo2 is a powerful marker of prognosis for patients with CHF whether they are taking beta blockers or not. A low heart rate response to exercise in patients with CHF correlates with worse exercise tolerance but is unlikely to contribute to exercise impairment.
OBJECTIVE: To establish the prevalence of chronotropic incompetence in a cohort of patients with chronic heart failure (CHF) taking modern medications for heart failure, and whether this affected exercise capacity and predicted prognosis. METHODS: Heart rate response to exercise was examined in 237 patients with CHF in sinus rhythm, who were compared with 118 control volunteers. The percentage of maximum age predicted peak heart rate (%Max-PPHR) and percentage heart rate reserve (%HRR) were calculated, with a cut off of < 80% as the definition of chronotropic incompetence for both. Patients were followed up for an average (SD) of 2.8 (9) years. Mortality was related to peak oxygen consumption (pVo2), and the presence or absence of chronotropic incompetence. RESULTS: %Max-PPHR < 80% identified 103 (43%) and %HRR < 80% identified 170 patients (72%) as having chronotropic incompetence. Chronotropic incompetence was more common in patients taking beta blockers than in those not taking beta blockers as assessed by both methods (80 (49%) v 23 (32%) by %Max-PPHR and 123 (75%) v 47 (64%) by %HRR, respectively). Patients with chronotropic incompetence by either method had a lower pVo2 than those without. These differences remained significant for both patients taking and not taking a beta blocker. %HRR, Max-PPHR%, and HRR were related to New York Heart Association class and correlated with pVo2. There was no difference in the slopes relating heart rate to pVo2 between patients with and those without chronotropic incompetence (6.1 (1.7) v 5.1 (1.8), p = 0.34). During an average 2.8 year follow up 40 patients (17%) died. In Cox proportional hazard models, pVo2 was the most powerful predictor of survival and neither measure of chronotropic incompetence independently predicted outcome. CONCLUSIONS:pVo2 is a powerful marker of prognosis for patients with CHF whether they are taking beta blockers or not. A low heart rate response to exercise in patients with CHF correlates with worse exercise tolerance but is unlikely to contribute to exercise impairment.
Authors: Klaus K A Witte; Simon Thackray; Nikolay P Nikitin; John G F Cleland; Andrew L Clark Journal: Eur J Heart Fail Date: 2005-06 Impact factor: 15.534
Authors: S J Keteyian; C A Brawner; J R Schairer; T B Levine; A B Levine; F J Rogers; S Goldstein Journal: Am Heart J Date: 1999-08 Impact factor: 4.749
Authors: Maggie Kam Man Ma; Ming Lang Zuo; Desmond Yat Hin Yap; Maggie Ming Yee Mok; Lorraine Pui Yuen Kwan; Gary Chi Wang Chan; David Chung Wah Siu; Tak Mao Chan Journal: J Nephrol Date: 2014-04-23 Impact factor: 3.902
Authors: Daniel E Forman; Robert Clare; Dalane W Kitzman; Stephen J Ellis; Jerome L Fleg; Toni Chiara; Gerald Fletcher; William E Kraus Journal: Am Heart J Date: 2009-10 Impact factor: 4.749
Authors: Daniela Dobre; Faiez Zannad; Steven J Keteyian; Susanna R Stevens; Patrick Rossignol; Dalane W Kitzman; Joel Landzberg; Jonathan Howlett; William E Kraus; Stephen J Ellis Journal: Eur Heart J Date: 2013-01-12 Impact factor: 29.983
Authors: Kumar Dharmarajan; Angela F Hsieh; Zhenqiu Lin; Héctor Bueno; Joseph S Ross; Leora I Horwitz; José Augusto Barreto-Filho; Nancy Kim; Susannah M Bernheim; Lisa G Suter; Elizabeth E Drye; Harlan M Krumholz Journal: JAMA Date: 2013-01-23 Impact factor: 56.272